EFFECT OF IFN-ALPHA AND IL-2 ON IN-VIVO GENERATION OF KILLER CELLS

IFN-α和IL-2对体内杀伤细胞生成的影响

基本信息

  • 批准号:
    3811184
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

In this project, we have studied in-vivo generation of LAK, NK, and CTL activities in response to IL-2 and IFN-alpha administration in the organs of mice. The data indicate that administration of IL-2 for 3 consecutive days is capable of generating LAK activity and enhance NK mediated cytotoxicity from splenic and hepatic lymphocytes. Administration of a mixture of IFN-alpha and IL-2 enhanced LAK activity compared to group treated with IL- alone. In both spleen and liver cells, LAK activity was enhanced. The induction of NK activity was also observed by IFN-alpha and IL-2 administration but the results were variable. Continued administration of IFN-alpha and IL-2 for 7 days caused synergistic augmentation of LAK activity in both liver and spleen cells. IL-2 administration alone caused generation of LAK but activity was lower than observed after 3 days of therapy. These studies indicate that potent LAK or 'super LAK' cells are generated by IL-2 and IFN-alpha-therapy in vivo and this may explain, at least in part, the synergistic anti-tumor effects of this combination therapy in mouse as well as in man. We have also analysed the phenotype of proliferating cells in the spleens and livers of mice from various treatmen groups. IL-2 administration caused an increase in the percentage Thy 1.2 an Asialo-GM-1 positive cells in both organs. The administration of both IL-2 and IFN-alpha also increased Thy 1.2 and Asialo-GM-1 positive cells and thi increase in the liver appeared to be greater than caused by IL-2 alone. The CTL response is currently being investigated.
本课题研究了LAK、NK和CTL的体内诱导 器官中响应IL-2和IFN-α给药的活性 的 小鼠数据表明连续3天施用IL-2 能够产生LAK活性并增强NK介导的细胞毒性 脾和肝淋巴细胞中提取。施用以下物质的混合物: IFN-α和IL-2增强LAK活性 一个人脾细胞和肝细胞LAK活性增强。的 IFN-α和IL-2也可诱导NK细胞活性 但结果是可变的。继续给药 IFN-α和IL-2联合作用7天可协同增强LAK细胞活性 在肝和脾细胞中的活性。IL-2单独给药引起 产生LAK,但活性低于3天后观察到的 疗法这些研究表明,有效的LAK或“超级LAK”细胞是 产生的IL-2和IFN-α-治疗在体内,这可以解释,在 至少部分地,该组合的协同抗肿瘤作用 在小鼠和人的治疗中,我们还分析了 不同处理小鼠脾和肝中增殖细胞 组IL-2给药引起Thy 1.2和Thy 1.4百分比的增加, 两个器官中的去唾液酸GM-1阳性细胞。IL-2的施用 IFN-α也增加Thy 1.2和Asialo-GM-1阳性细胞, 肝脏中的增加似乎大于单独由IL-2引起的。的 目前正在研究CTL应答。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

R PURI其他文献

R PURI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('R PURI', 18)}}的其他基金

INTERLEUKINS AND THEIR RECEPTORS IN TUMOR BIOLOGY AND AIDS
肿瘤生物学和艾滋病中的白细胞介素及其受体
  • 批准号:
    6161309
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
IL-4 RECEPTORS ON MURINE SOLID TUMORS AND TUMOR INFILTRATING LYMPHOCYTES
鼠实体瘤和肿瘤浸润淋巴细胞上的 IL-4 受体
  • 批准号:
    3804728
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
INTERLEUKINS AND THEIR RECEPTORS IN TUMOR BIOLOGY AND AIDS
肿瘤生物学和艾滋病中的白细胞介素及其受体
  • 批准号:
    2568987
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
INTERLEUKIN-4 AND THEIR RECEPTORS IN TUMOR BIOLOGY AND AIDS
肿瘤生物学和艾滋病中的 INTERLEUKIN-4 及其受体
  • 批准号:
    3770375
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
CHARACTERIZATION OF TUMORS AND TIL FROM TUMORS INDUCED BY HHV-6
HHV-6 诱导的肿瘤和 TIL 的特征
  • 批准号:
    3804729
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
EXPRESSION OF IL-4 RECEPTORS ON HUMAN TUMORS
IL-4 受体在人类肿瘤上的表达
  • 批准号:
    3792452
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
IMMUNOREGULATION IN VIVO AND IN VITRO BY CYTOKINES
细胞因子的体内和体外免疫调节
  • 批准号:
    3792449
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
INTERLEUKIN-4 AND THEIR RECEPTORS IN TUMOR BIOLOGY AND AIDS
肿瘤生物学和艾滋病中的 INTERLEUKIN-4 及其受体
  • 批准号:
    5200774
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
EXPRESSION OF IL-4 RECEPTORS ON HUMAN TUMORS
IL-4 受体在人类肿瘤上的表达
  • 批准号:
    3804731
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
IMMUNOREGULATION IN VIVO AND IN VITRO BY CYTOKINES
细胞因子的体内和体外免疫调节
  • 批准号:
    3804727
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Proton radiation therapy combined with immunotherapy for enhancing antitumor immune responses in pancreatic cancer murine models.
质子放射治疗与免疫治疗相结合,增强胰腺癌小鼠模型的抗肿瘤免疫反应。
  • 批准号:
    24K10423
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel cancer immunotherapy model targeting human macrophages
开发针对人类巨噬细胞的新型癌症免疫治疗模型
  • 批准号:
    24K18516
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of a comprehensive microbial immunotherapy platform with immuno-transcriptomic monitoring for treatment of bladder cancer (DOCMI-BC)
开发用于治疗膀胱癌的具有免疫转录组监测的综合微生物免疫治疗平台(DOCMI-BC)
  • 批准号:
    10087336
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Collaborative R&D
In vivo function-persistent polymersome nanoreactor with tumor-specific activation and safe clearance/metabolism for synergistic oxidation-chemo-immunotherapy
具有肿瘤特异性激活和安全清除/代谢作用的体内功能持久聚合物纳米反应器,用于协同氧化-化学-免疫治疗
  • 批准号:
    24K21109
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Indication selection, patient stratification, and IND preparation for STX-002: the first-in-class LRG1 inhibitor for treatment of chronic kidney disease and immunotherapy-resistant tumours.
STX-002的适应症选择、患者分层和IND准备:用于治疗慢性肾病和免疫治疗耐药肿瘤的一流LRG1抑制剂。
  • 批准号:
    10092585
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Collaborative R&D
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
  • 批准号:
    10751872
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
Spatial-BrTME: Multicellular spatial dynamics of immunotherapy response in breast cancer
Spatial-BrTME:乳腺癌免疫治疗反应的多细胞空间动力学
  • 批准号:
    EP/Y014995/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Develop the novel targets and immunotherapy-combination agents through targeting nuclear transport receptor
以核转运受体为靶点开发新靶点和免疫治疗联合药物
  • 批准号:
    24K13116
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineering Biology for the Treatment of Solid Tumours : Enhancing T Cell Function and Longevity in the Tumour Microenvironment for Improved Cancer Immunotherapy
治疗实体瘤的工程生物学:增强肿瘤微环境中的 T 细胞功能和寿命,以改善癌症免疫治疗
  • 批准号:
    10074648
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant for R&D
Living in limbo: The Experience of and Relationship between Fear of Progression, Illness Uncertainty, Symptom Burden, and Death Anxiety in Patients with Advanced or Metastatic Lung Cancer Receiving Immunotherapy or Targeted Therapy
生活在不确定之中:接受免疫治疗或靶向治疗的晚期或转移性肺癌患者对病情进展的恐惧、疾病的不确定性、症状负担和死亡焦虑的经历和关系
  • 批准号:
    478587
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了